INTRODUCTION
By using DNA microarray techniques, it has been shown that breast cancers can be classified into biologically distinct groups based on their gene expression profiles [1] . These groups comprise luminal A (estrogen receptor and triple negative (ER-and HER2-negative) subtypes [2] .
TNBC is a heterogeneous group and is further categorized into the basal-phenotype (BP) and non-BP groups, which are positive and negative, respectively, for myoepithelial/ basal markers such as basal cytokeratins (CKs) (i.e., CK5/6, CK14, and CK17), and epidermal growth factor receptor (EGFR) [3, 4] . Although TNBCs account for only 10 to 17% of all breast carcinomas, this subgroup is regarded as important clinically because of the aggressive clinical behavior, poorer patient prognosis, and lack of an established therapeutic target [5] . ER, estrogen receptor; RT, room temperature; PgR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; FISH, fluorescent in situ hybridization; CK, cytokeratin; bcl-2, B-cell lymphoma. TNBC was estimated to be up to 56 to 84%. Among the genes regulators of the apoptotic process, the tumor suppressor gene p53 and the B-cell lymphoma (bcl)-2 gene and its family members have been studied in clinical settings of breast cancer [1, 6] . Among the several biomarkers, bcl-2 is an anti-apoptotic gene, and it is a poor prognostic factor in various malignant tumors. However, the prognostic significance of bcl-2 expression in breast cancer remains controversial [7] . We retrospectively applied these factors to our series of TNBC patients, in conjunction with an evaluation of the prognostic significance of these factors influencing TNBC survival rate. Particular focus was placed on the role of CK5/6, EGFR, bcl-2, and p53. 
METHODS

Immunohistochemical techniques
The expression of ER, PgR, HER-2/neu, CK5/6 and other biological markers was determined immunohistochemically in paraffin-embedded tissue specimens [1, 6] . was 10% and this was taken as the cut-off point distinguishing slowly from quickly proliferating tumors. The slides were scored by the same pathologist. We considered the tumor positive for p53 and bcl-2 when 10% or more of the cells counted were stained [7, 10] .
Statistical analysis
Statistical tests were performed using the SPSS ver. and differences in survival were analyzed using the log rank test. Associations between specific histopathological and clinical survival estimates and curves were established using the Kaplan-Meier method and differences in observed survival distribution among patient subgroups were tested with two-sided log-rank test. All survival rates were presented with their standard errors. We used
Pearson's correlation to determine the association of pairs of explanatory variables, differences in qualitative variables were evaluated by chi-squared test, where necessary.
The survival differences between patients with a basal phenotype TNBC and a non-BP TNBC were calculated with the Cox proportional hazards model. A P-value of ＜0.05 was considered to indicate statistical significance.
All P-values were two-sided and a P-value of less than 0.05 was considered to indicate a statistically significant difference.
RESULTS
The main clinicopathological characteristics of the patients in our series are summarized in Table 2 Values are presented as number (%). AJCC, American Joint Committee on Cancer; EGFR, epidermal growth factor receptor; CK, cytokeratin; bcl-2, B-cell lymphoma. was also significant (P = 0.008, P = 0.008 respectively) ( Table   6 ). Also, the univariate analysis for prognostic factors associated with OS revealed that Ki-67, CK5/6 was statistically significant (P = 0.047, P = 0.036 respectively) (Figs.
1-4)
. Lymph node stage group as N0, N1, N2, or N3 was also statistically significant (P = 0.022) ( Table 7) . 
DISCUSSION
Apoptosis, or programmed cell death, plays a major role not only in the formation and progression of cancer, but in the development of resistances to anticancer drugs as well [11] . The genes p53 and bcl-2 play an important role in regulating the mechanisms of apoptosis [12] . p53 is a tumor suppressor gene involved in the regulation of proliferative activity of human cells. Indeed, p53 serves a multifunctional role as a transcriptional regulator, genomic stabilizer, inhibitor of cell cycle progression, facilitator of apoptosis and also perhaps as inhibitor of angiogenesis [13] . By all these mechanisms, wild type p53 slows proliferation, while mutations of these gene in cancer cells may result in higher proliferation rates, higher genetic instability, and resistance to apoptosis [14] . Many studies have analyzed the prognostic impact of p53 alterations in breast cancer, and most of the studies have reported an association with worse outcome, either in node negative and node positive disease. However, others studies failed to demonstrate a significant association of p53 with poorer prognosis [8, 11, 15] . In our series, p53 over-expression was found in 60.0% of breast cancers, a value in line with the reported values between 11 and 60% of p53 mutation in breast cancer by immunohistochemistry, but did not correlate to either bcl-2 expression or to disease-free and overall survival. It has been recently accepted that gene sequencing is the most appropriate method to study p53 status; indeed different types of mutated p53 oncogene exist that do not determine protein accumulation and are therefore not detected by immunohistochemistry [15, 16] . The discordance between our results and other studies may be partly due to the immunohistochemical technique used to detect p53 mutations and reflects the inconsistent data reported in literature for p53 mutation in breast cancer. The bcl-2 gene was initially identified in human bcls and its activity as apoptosis inhibitor, either drug and p53 induced, in cancer cells has been well demonstrated [7, 10] . As a consequence, the expression of bcl-2 in breast cancer cells
thesurgery.or.kr should inhibit apoptosis and therefore relate to a worse outcome [1] . On the contrary, the expression of bcl-2 in breast cancer has been found to be associated with favorable prognostic factors such as small tumor size, ER positivity, low nuclear grade and to predict a better outcome [7, 10, 17] . These unexpected results may be explained by the fact that the ability of bcl-2 to inhibit apoptosis depends on the intracellular balance among a number of its family members, with other pro-apoptotic members such as Bax counteracting its action [7, 18] . Given its antiapoptotic function, bcl-2 should be expected to correlate with worse prognosis. On the contrary, high levels of bcl-2 expression have been reported as associated to favorable tumor characteristics, such as low tumor size, low tumor grade, low proliferative activity and mainly with expression of ER and PgR [19] . These associations account for the favorable prognostic impacts reported for bcl-2 expression on DFS and OS in breast cancer, either node negative and node positive, even if an independent prognostic role has been confirmed only in some series [20, 21] . Our In conclusion, paradoxically, CK5/6 positive TNBCs are higher DFS and OS than CK5/6 negative TNBCs. So, our study has some limitations in that CK5/6 can be used to classify TNBCs into at least two subtypes with differing survival rates. Also, the nuclear proliferation antigen, Ki-67, can be used to differentiate disease-free survival.
But markers regulating cell cycle and cell death such as p53 and bcl-2 cannot be used to classify TNBCs into two subtypes with differing survival rates. However, because our study is small in size, there is no survival difference between TNBC groups according to basal type. So, more abundant patients' data will be needed to evaluate the pro-apoptotic activity of other members of the bcl-2 family's predictive role.
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